ESMO | European Society for Medical Oncology
ESMO 2024
PD-1 Inhibitors Have Shown Remarkable Efficacy
- / BestPractice Nordic
Bladder Cancer: The Danish TOMBOLA Shows Practice Changing Results
/ BestPractice Nordic
ESMO 2024: Presentations and Perspectives of New Data at Norwegian Evening
/ BestPractice Nordic
2023
Optimizing PARP Inhibitor Therapy for Ovarian Cancer
/ Mansoor Raza Mirza
Enabling Patient Empowerment Through Digital Monitoring
/ Ellinor Christin Haukland
ESMO 2022
More from ESMO 2022
ESMO 2022 –” Understanding the disease to provide better care for cancer patients”
/ BestPractice Nordic
ESMO 2021
First-line niraparib is associated with improvement in QA-PFS and QA-TWiST
/ Ma Pilar Barretina-Ginesta